FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3001497679> ?p ?o ?g. }

• W3001497679 endingPage "284" @default.
• W3001497679 startingPage "275" @default.
• W3001497679 abstract "Treatment options for relapsed or refractory diffuse large B-cell lymphoma (RR DLBCL) represent an unmet medical need. Apatinib is a new oral tyrosine kinase inhibitor mainly targeting vascular endothelial growth factor receptor-2 (VEGFR-2) to inhibit tumour angiogenesis. In the present study, we evaluated the efficacy and safety of apatinib for patients with RR DLBCL.In this phase II, open-label, single-arm, prospective study, we enrolled patients aged 14-70 years with treatment failure of at least two chemotherapeutic regimens using Simon's two-stage design. All patients were administered apatinib at an initial dose of 500 mg on a 4-week cycle at home and visited the outpatient clinic every two cycles to evaluate efficacy and to record adverse events. We considered objective response rate (ORR) as the primary end point, and progression-free survival (PFS), and overall survival (OS) plus duration of response (DoR) as the secondary end point. (This trial was registered at ClinicalTrials.gov, identifier: NCT03376958.).From January 2017 to February 2019, we screened 35 patients and enrolled 32 eligible patients. At the cutoff point (April 2019), we noted 2 (6.3%) complete responses, 12 (37.5%) partial responses, and 9 (28.1%) stable diseases, attributing to an ORR of 43.8% and a disease control rate of 71.9%. The median PFS and OS were 6.9 (95% confidence interval [CI], 5.8-7.9) and 7.9 months (95% CI, 7.0-8.7), respectively. The median DoR was 5.0 months (95% CI, 3.5-6.5) for patients who achieved PR. The most common grade 3-4 adverse events (AE) were hypertension (12.6%), hand-foot syndrome (9.4%), and leucopenia (6.3%). No apatinib-related deaths were noted.Home administration of apatinib shows promising efficacy and manageable AEs in patients with RR DLBCL." @default.
• W3001497679 created "2020-01-30" @default.
• W3001497679 creator A5000802348 @default.
• W3001497679 creator A5007823796 @default.
• W3001497679 creator A5010480280 @default.
• W3001497679 creator A5019544133 @default.
• W3001497679 creator A5022526821 @default.
• W3001497679 creator A5029441253 @default.
• W3001497679 creator A5044104650 @default.
• W3001497679 creator A5048995364 @default.
• W3001497679 creator A5050257179 @default.
• W3001497679 creator A5072036342 @default.
• W3001497679 creator A5076701232 @default.
• W3001497679 creator A5077909382 @default.
• W3001497679 creator A5080214203 @default.
• W3001497679 creator A5081896829 @default.
• W3001497679 creator A5089378544 @default.
• W3001497679 creator A5090591783 @default.
• W3001497679 date "2020-01-01" @default.
• W3001497679 modified "2023-10-18" @default.
• W3001497679 title "<p>Apatinib in Patients with Relapsed or Refractory Diffuse Large B Cell Lymphoma: A Phase II, Open-Label, Single-Arm, Prospective Study</p>" @default.
• W3001497679 cites W1020989877 @default.
• W3001497679 cites W1816099873 @default.
• W3001497679 cites W1982283280 @default.
• W3001497679 cites W2011237998 @default.
• W3001497679 cites W2018071905 @default.
• W3001497679 cites W2029409133 @default.
• W3001497679 cites W2033366833 @default.
• W3001497679 cites W2049141040 @default.
• W3001497679 cites W2051342405 @default.
• W3001497679 cites W2066775791 @default.
• W3001497679 cites W2070782305 @default.
• W3001497679 cites W2091774189 @default.
• W3001497679 cites W2105968397 @default.
• W3001497679 cites W2127018518 @default.
• W3001497679 cites W2133201432 @default.
• W3001497679 cites W2136060045 @default.
• W3001497679 cites W2143901303 @default.
• W3001497679 cites W2170030318 @default.
• W3001497679 cites W2276228008 @default.
• W3001497679 cites W2461273885 @default.
• W3001497679 cites W2556207462 @default.
• W3001497679 cites W2564665116 @default.
• W3001497679 cites W2578710297 @default.
• W3001497679 cites W2582696216 @default.
• W3001497679 cites W2594496607 @default.
• W3001497679 cites W2605009867 @default.
• W3001497679 cites W2747382292 @default.
• W3001497679 cites W2751140959 @default.
• W3001497679 cites W2773804840 @default.
• W3001497679 cites W2782478748 @default.
• W3001497679 cites W2791328450 @default.
• W3001497679 cites W2793587264 @default.
• W3001497679 cites W2883371432 @default.
• W3001497679 cites W2885573907 @default.
• W3001497679 cites W2886354380 @default.
• W3001497679 cites W2888017322 @default.
• W3001497679 cites W2899591632 @default.
• W3001497679 cites W2909334052 @default.
• W3001497679 cites W2911931027 @default.
• W3001497679 doi "https://doi.org/10.2147/dddt.s227477" @default.
• W3001497679 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6986930" @default.
• W3001497679 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32158186" @default.
• W3001497679 hasPublicationYear "2020" @default.
• W3001497679 type Work @default.
• W3001497679 sameAs 3001497679 @default.
• W3001497679 citedByCount "6" @default.
• W3001497679 countsByYear W30014976792020 @default.
• W3001497679 countsByYear W30014976792021 @default.
• W3001497679 countsByYear W30014976792023 @default.
• W3001497679 crossrefType "journal-article" @default.
• W3001497679 hasAuthorship W3001497679A5000802348 @default.
• W3001497679 hasAuthorship W3001497679A5007823796 @default.
• W3001497679 hasAuthorship W3001497679A5010480280 @default.
• W3001497679 hasAuthorship W3001497679A5019544133 @default.
• W3001497679 hasAuthorship W3001497679A5022526821 @default.
• W3001497679 hasAuthorship W3001497679A5029441253 @default.
• W3001497679 hasAuthorship W3001497679A5044104650 @default.
• W3001497679 hasAuthorship W3001497679A5048995364 @default.
• W3001497679 hasAuthorship W3001497679A5050257179 @default.
• W3001497679 hasAuthorship W3001497679A5072036342 @default.
• W3001497679 hasAuthorship W3001497679A5076701232 @default.
• W3001497679 hasAuthorship W3001497679A5077909382 @default.
• W3001497679 hasAuthorship W3001497679A5080214203 @default.
• W3001497679 hasAuthorship W3001497679A5081896829 @default.
• W3001497679 hasAuthorship W3001497679A5089378544 @default.
• W3001497679 hasAuthorship W3001497679A5090591783 @default.
• W3001497679 hasBestOaLocation W30014976791 @default.
• W3001497679 hasConcept C121332964 @default.
• W3001497679 hasConcept C121608353 @default.
• W3001497679 hasConcept C126322002 @default.
• W3001497679 hasConcept C141071460 @default.
• W3001497679 hasConcept C142424586 @default.
• W3001497679 hasConcept C143998085 @default.
• W3001497679 hasConcept C188816634 @default.
• W3001497679 hasConcept C197934379 @default.
• W3001497679 hasConcept C203092338 @default.
• W3001497679 hasConcept C2776694085 @default.

• next